Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.32 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18740345 | 0.88 | LGALS8 (0.36) | FGF1LGALS8SSTR5 | |
| SCHEMBL14998755 | 0.84 | FGF1 (0.39) | FGF1SERPINC1 | |
| SCHEMBL14124121 | 0.82 | FGF1 (0.42) | FGF1SERPINC1SSTR5 | |
| SCHEMBL15281442 | 0.80 | FGF1 (0.45) | FGF1SERPINC1SSTR5 | |
| SCHEMBL7147865 | 0.80 | FGF1 (0.45) | FGF1SERPINC1SSTR5 | |
| SCHEMBL2745005 | 0.80 | FGF1 (0.45) | FGF1SERPINC1SSTR5 | |
| SCHEMBL7151360 | 0.80 | FGF1 (0.45) | FGF1SERPINC1SSTR5 | |
| SCHEMBL15281431 | 0.80 | FGF1 (0.45) | FGF1SERPINC1SSTR5 | |
| SCHEMBL12082938 | 0.80 | FGF1 (0.45) | FGF1SERPINC1SSTR5 | |
| SCHEMBL10943934 | 0.80 | FGF1 (0.45) | FGF1SERPINC1SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362564-B1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | AQUINNAH PHARMACEUTICALS INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20190142860-A1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-16 | — | — | US | disclosed |
| EP-3362564-A1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | Aquinnah Pharmaceuticals Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066657-A1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | AQUINNAH PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142860-A1 | NUCLEIC ACID BASED TIA-1 INHIBITORS | TIA1, TIAL1, TIAM1 | FGF1 1803/4885SERPINC1 1695/4885LGALS8 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.